0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Neurological Review |

F-Box Only Protein 7 Gene in Parkinsonian-Pyramidal Disease FREE

Hao Deng, MD, PhD; Hui Liang, MD; Joseph Jankovic, MD
[+] Author Affiliations

Author Affiliations: Center for Experimental Medicine (Drs Deng and Liang) and Department of Neurology (Dr Deng), the Third Xiangya Hospital, Central South University, Changsha, Hunan, China; and Department of Neurology, Baylor College of Medicine, Houston, Texas (Dr Jankovic).


SECTION EDITOR: DAVID E. PLEASURE, MD

More Author Information
JAMA Neurol. 2013;70(1):20-24. doi:10.1001/jamaneurol.2013.572.
Text Size: A A A
Published online

Parkinson disease is one of the most common neurodegenerative diseases associated with aging. At least 18 genetic loci and 13 disease-related genes for parkinsonism have been identified. Among them, PARK15 -associated parkinsonism, also referred to as parkinsonian-pyramidal disease (PPD), was found to be caused by mutations in the F-box only protein 7 gene (FBXO7). Parkinsonian-pyramidal disease differs from typical Parkinson disease chiefly by juvenile onset and the presence of spasticity. Four mutations have been identified and a pattern of autosomal recessive inheritance has been proposed in all reported PPD families. The FBXO7 protein is a member of the Skp1-Cullin-F-box–type E3 ubiquitin ligases, which play important roles in targeting proteins for ubiquitination. Although PPD is a relatively rare parkinsonian disorder, understanding its genetic and pathological mechanisms may lead to new insights into the pathogenesis of Parkinson disease and development of therapeutic strategies not only for PPD but also for other parkinsonian disorders.

Figures in this Article

Parkinson disease (PD, OMIM 168600) is the second most common neurodegenerative disorder after Alzheimer disease, with about 1% of the general population older than 65 years affected.1 Progressive and selective loss of nigrostriatal dopaminergic neurons and accumulation of aggregated α-synuclein in the nervous system have been considered critical for the pathological diagnosis of PD.2 Despite intense interest in the scientific community, the pathogenesis of PD is still elusive, although there is growing evidence supporting the role of genetic factors in the pathogenesis of PD and related parkinsonian disorders. To date, 13 disease-related genes and at least 18 genetic loci for parkinsonism have been identified through linkage analyses of family members (PARK1-15) or genome-wide association studies of index patients (PARK16-18) (Table 1).38

Table Graphic Jump LocationTable 1. Genetic Loci and Genes Associated With Monogenic Forms of Parkinson Disease38

Parkinson disease is a complex disease characterized by the presence of cardinal motor signs including tremor at rest, rigidity, bradykinesia, and loss of postural reflexes.9 In addition to these and other motor signs, there is growing recognition that nonmotor symptoms may be as, or even more, troublesome for many patients.9 Parkinsonian-pyramidal disease (PPD, OMIM 260300) is a rare entity, characterized by juvenile onset and pyramidal tract signs. A genome-wide linkage analysis and sequencing in a large Iranian pedigree found a mutation in the F-box only protein 7 gene (FBXO7, OMIM 605648) as the cause of PPD.10 FBXO7 protein is 1 of 4 subunits of ubiquitin protein ligases called Skp1-Cullin-F-box, which are involved in substrate recognition and recruitment for ubiquitination and consequent degradation by the proteasome.11 The ubiquitin proteasome system impairment has been implicated in the pathogenesis of PD and it may also participate in the pathogenesis of FBXO7 -caused PPD.2 In this article, we provide a systematic review of the clinical, pathological, and genetic features of PPD and explore the pathogenic relationship between PPD and the FBXO7 gene.

In 1954, Davison12 described 5 patients with juvenile-onset parkinsonism and pyramidal tract signs, labeled as pallido-pyramidal disease. Parkinsonian-pyramidal disease consists of the combination of parkinsonism and pyramidal features, but cerebellar symptoms have been also described in rare cases.13 In addition to the typical parkinsonian features such as rest tremor, rigidity, bradykinesia, hypomimia, and monotonous speech, patients with PPD also exhibit childhood-onset pyramidal tract signs, including Babinski sign, hyperreflexia, and spasticity with equinovarus deformity.10,12 Cerebellar signs might appear in the initial stages but become less apparent and may even fade away as the disease progresses.10 Of the patients with PPD reported so far, the onset is usually in childhood or young adulthood with unilateral slowness or incoordination, but the symptoms become symmetrical after several years, progress relatively slowly, and exhibit good and sustained improvement of their parkinsonian symptoms with levodopa.10,13 Most reported cases have been familial and associated with parental consanguinity, consistent with an autosomal recessive mode of transmission.10

Given the presence of nonspecific degeneration without inclusions, involving the pallidum, substantia nigra, and pyramidal tract, observed in the postmortem examination of the initial patient, Davison12 proposed the designation of PPD in the original report. Pathological study showed degenerative changes in the globus pallidus and ansa lenticularis, with relative preservation of the putamen and caudate nuclei. The substantia nigra was described as “shrunken in size.”14 In addition, the autopsied brains showed evidence of depigmentation of the locus caeruleus and demyelination in the pyramids and in the crossed pyramidal tracts of the spinal cord.14 Since not all reported cases with the PPD phenotype exhibited pyramidal or pallidal lesions, the designation of PPD has been challenged.15 Furthermore, functional imaging, such as positron emission tomography and single photon emission computed tomography, showed decreased metabolism in the striatum rather than pallidum.13,16 Other disorders with the PPD phenotype include the Kufor-Rakeb syndrome (caused by loss-of-function mutation in the ATP13A2 gene) and other autosomal recessive forms of juvenile parkinsonism (caused, for example, by mutations in the parkin, PINK1, DJ-1, and PLA2G6 genes).15,1719 Although PPD has similarities to the Kufor-Rakeb syndrome (PARK9, OMIM 606693), the latter tends to manifest with coexistent dementia and upgaze oculomotor palsy.17 The phenotypes associated with parkin (PARK2, OMIM 600116), PINK1 (PARK6, OMIM 605909), and DJ-1 (PARK7, OMIM 606324) overlap with early-onset PD, and pyramidal tract signs associated with these gene mutations are mild or not evident.18,19 Patients with PLA2G6 (PARK14, OMIM 612953) mutations are characterized by levodopa-responsive dystonia-parkinsonism, pyramidal tract signs, and cognitive/psychiatric features without pallidal and nigral iron deposition.19,20 Thus, patients with childhood- or young adult–onset parkinsonism, pyramidal tract signs, ataxia, dystonia, and equinovarus deformity, without known autosomal recessive gene mutations including ATP13A2, parkin, PINK1, DJ-1, and PLA2G6, should be considered for testing for FBXO7 gene mutations.

Mutations in the FBXO7 gene have been found to be associated with the development of early-onset autosomal recessive PPD.10,21 The FBXO7 gene, mapped to chromosome 22q12.3, contains 9 exons spanning about 24.1 kilobases.11,21 It encodes a protein of 522 amino acids consisting of several discrete domains: the ubiquitin-like domain, cyclin-dependent protein kinase 6 (CDK6) binding site, FBXO7/PI31 domain, F-box motif, proline-rich region, and R(ar)DP motif (Figure).11,21 FBXO7 is a member of the F-box–containing protein family, which is defined by the presence of an F-box domain.11 Four transcript variants (2 of them have been annotated in GenBank, NM_012179.3 and NM_001033024.1, and the other 2 variants had been identified by Di Fonzo et al21) had been found to rely on alternative combinations of exons 1A or 1B with exons 2A or 2B.21 Isoform 1 is the longest transcript and more abundant, particularly in primary skin fibroblasts.22 It is longer than isoform 2 because of the presence of an N terminal ubiquitin-like domain (absent in isoform 2), which is thought to interact with ubiquitin receptor proteins.22 The FBXO7 gene is ubiquitously expressed as a 2.15-kilobase transcript in fetal liver, bone marrow, human brain, heart, kidney, liver, lung, skeletal muscle, pancreas, and placenta.11

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Transcript 1 and isoform 1 of FBXO7. CDK indicates cyclin-dependent protein kinase 6 binding site; FP, FBXO7/PI31 domain; PRR, proline-rich region; and Ubl, ubiquitin-like domain.

Four different types of the FBXO7 mutations were described in the literature (Table 2).10,21 Linkage analysis of an Iranian PPD pedigree identified a disease locus (PARK15, OMIM 260300) on chromosome 22, and a homozygous missense mutation (R378G) in FBXO7 was proposed as the likely disease-causing variant.10 R378 lies within a well-conserved region of the protein and within a completely conserved -RDF- motif. It is completely conserved in all FBXO7 proteins, even in distally related species (human and the purple sea urchin). The affected individuals harbored the homozygous R378G mutation and the heterozygous family member was unaffected.10 A homozygous truncating mutation (R498X), which removes 25 amino acids from the C terminal, crucial for F-box–containing proteins' target specificity, was found in 3 families from Italy, Pakistan, and southeast Turkey, all exhibiting dystonia as part of the phenotype.21,23 Compound heterozygous mutations (a splice-site IVS7 + 1G/T mutation and a missense T22M mutation) were found in a Dutch family.21 The IVS7 + 1G/T mutation removes the invariable splice donor of intron 7 and it may disrupt FBXO7 messenger RNA splicing. The T22M mutation replaces a highly conserved amino acid in the N terminal ubiquitin-like domain, which is associated with nucleus localization of the FBXO7 protein and is only expressed in the 2 longer FBXO7 isoforms (isoform 1 and isoform 3).21,22 No pathogenic FBXO7 gene mutations were found in Chinese patients with early-onset parkinsonism (most without hyperreflexia or other pyramidal signs), further supporting the notion that PPD is a clinically heterogenous neurodegenerative disorder characterized by a variable combination of parkinsonism, dystonia, and pyramidal tract signs.24

Table Graphic Jump LocationTable 2. Pathogenic Mutations in the FBXO7 Gene in Patients With Parkinsonian-Pyramidal Disease

The FBXO7 protein belongs to the F-box–containing protein group, which is 1 of the 4 subunits of ubiquitin protein ligases called Skp1-Cullin-F-box, and interacts specifically with Skp1 through its F-box.11 F-box only protein 7 can interact with 3 proteins including hepatoma upregulated protein, the inhibitor of apoptosis protein 1, and the proteasome inhibitor protein PI31.2527 F-box only protein 7 may mediate substrates' ubiquitination, resulting in possible degradation and altered function, assembly, or localization of these FBXO7-interacted proteins.26,27 Cell survival signals represent 2 opposite extremes such as cell proliferation in cancer and cell death due to apoptosis in PD. Recessive PD-caused genes including parkin, PINK1, and FBXO7 were found to exert an important role in carcinogenesis, and loss of function of these genes may result in neuron degeneration.28 Because impaired proteasome activity was found in patients with sporadic PD, the finding that PI31 acts in vitro as an inhibitor of proteasome activity may be relevant to its role in neurodegeneration.29 F-box only protein 7 was reported to selectively enhance activity of CDK6, which plays a critical role in regulating a diverse set of cellular processes and neuronal death processes.30 Intriguingly, CDK5 accumulated in the Lewy bodies of brains of patients with PD and an increase in CDK5 levels and activity has been observed in an MPTP mouse model of PD.31 The mechanism by which FBXO7 causes PPD involving the CKD family should be further investigated because it may provide insights into the pathogenesis of PD and related neurodegenerative disorders.

R378G lies at or near the right border of the F-box motif and approximately 45 amino acids upstream of the left border of the proline-rich region motif and may disrupt the function of either or both of these.10 A depressed level of the FBXO7 isoform 1 transcript was observed in patients with homozygous (R498X) or compound heterozygous (T22M and IVS7 + 1G/T) mutations, suggesting the loss of function or depletion of isoform 1 plays an important role in the pathogenesis of PPD. The missense T22M mutation of FBXO7 leads to mislocalization to the cytoplasm, affecting the interaction with other proteins that are crucial for the nuclear import of FBXO7. The overexpressed R498X mutant displays an abnormal pattern of diffuse, cytosolic, and nuclear localization, indicating that the C terminus of the protein might contain an important motif for nuclear import or export.22

The role of FBXO7 in neurons is still not known, although the ubiquitin-mediated protein degradation pathway clearly plays an important role in the pathogenesis of neurodegenerative diseases including PD.32 The FBXO7 gene encodes an E3 ligase, and pathogenic FBXO7 gene mutations are likely to induce protein dysfunction leading to abnormal ubiquitination. Loss of function is considered the chief mechanism in recessive disorders, such as PPD, and dysfunction of the mutated protein may lead to accelerated aging of dopaminergic neurons.24

Major advances in PD research have been made in the past decade with the discovery of a series of genes that are responsible for monogenic parkinsonian disorders. The genetic cause of PPD, a progressive autosomal recessive disorder manifested by childhood- or young-onset levodopa-responsive parkinsonism and variable presence of pyramidal tract signs, ataxia, and dystonia, has been recently elucidated. Mutations in FBXO7 have been found to result in loss of nuclear activity of the FBXO7 protein in patients with PPD. The various recessive mutations in FBXO7 result in changes that are concentrated in the functional region of this protein. Unraveling the FBOX7 pathways in neurons, especially as they relate to ubiquitination and the development of PPD, should provide insights into the molecular mechanisms of this neurodegenerative disorder, which in turn may lead to pathogenesis-targeted therapeutic strategy.

Correspondence: Hao Deng, MD, PhD, Center for Experimental Medicine, the Third Xiangya Hospital, Central South University, 138 Tongzipo Rd, Changsha, HN 410013, China (hdeng008@yahoo.com).

Accepted for Publication: March 14, 2012.

Published Online: October 1, 2012. doi:10.1001/jamaneurol.2013.572

Author Contributions: Drs Deng and Liang contributed equally to this work. Study concept and design: Deng and Liang. Acquisition of data: Deng and Liang. Analysis and interpretation of data: Deng, Liang, and Jankovic. Drafting of the manuscript: Deng and Liang. Critical revision of the manuscript for important intellectual content: Deng, Liang, and Jankovic. Obtained funding: Deng. Administrative, technical, and material support: Deng and Liang. Study supervision: Deng.

Financial Disclosure: None reported.

Funding/Support: This study was supported by the National Natural Science Foundation of China (grant 81101339); Research Fund for the Doctoral Program of Higher Education of China (grant 20110162110026); the Fundamental Research Funds for the Central Universities (grant 2011JQ014); the Construction Fund for Key Subjects of the Third Xiangya Hospital (Diagnostics of Clinical Laboratory), Central South University; Students Innovative Pilot Scheme of Central South University, China (grants YC10106, DL11446, and DL11447); and Graduate Degree Thesis Innovation Foundation of Central South University, China (grant 2011ssxt194).

Yang YX, Wood NW, Latchman DS. Molecular basis of Parkinson's disease.  Neuroreport. 2009;20(2):150-156
PubMed   |  Link to Article
Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease.  Ann Neurol. 2003;53:(suppl 3)  S16-S23, discussion S23-S25
PubMed   |  Link to Article
International Parkinson Disease Genomics Consortium. Nalls MA, Plagnol V, Hernandez DG,  et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.  Lancet. 2011;377(9766):641-649
PubMed   |  Link to Article
Simón-Sánchez J, Schulte C, Bras JM,  et al.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.  Nat Genet. 2009;41(12):1308-1312
PubMed   |  Link to Article
Vilariño-Güell C, Wider C, Ross OA,  et al.  VPS35 mutations in Parkinson disease.  Am J Hum Genet. 2011;89(1):162-167
PubMed   |  Link to Article
Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C,  et al.  Translation initiator EIF4G1 mutations in familial Parkinson disease.  Am J Hum Genet. 2011;89(3):398-406
PubMed   |  Link to Article
Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis.  Annu Rev Pathol. 2011;6:193-222
PubMed   |  Link to Article
Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease.  Annu Rev Genomics Hum Genet. 2011;12:301-325
PubMed   |  Link to Article
Jankovic J. Parkinson's disease: clinical features and diagnosis.  J Neurol Neurosurg Psychiatry. 2008;79(4):368-376
PubMed   |  Link to Article
Shojaee S, Sina F, Banihosseini SS,  et al.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays.  Am J Hum Genet. 2008;82(6):1375-1384
PubMed   |  Link to Article
Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C. cDNA cloning and expression analysis of new members of the mammalian F-box protein family.  Genomics. 2000;67(1):40-47
PubMed   |  Link to Article
Davison C. Pallido-pyramidal disease.  J Neuropathol Exp Neurol. 1954;13(1):50-59
PubMed   |  Link to Article
Kalita J, Misra UK, Das BK. Sporadic variety of pallido-pyramidal syndrome.  Neurol India. 2003;51(3):383-384
PubMed
Horowitz G, Greenberg J. Pallido-pyramidal syndrome treated with levodopa.  J Neurol Neurosurg Psychiatry. 1975;38(3):238-240
PubMed   |  Link to Article
Horstink MW, Dekker MC, Montagna P, Bonifati V, van De Warrenburg BP. Pallidopyramidal disease: a misnomer?  Mov Disord. 2010;25(9):1109-1115
PubMed   |  Link to Article
Panagariya A, Sharma B, Dev A. Pallido-pyramidal syndrome: a rare entity.  Indian J Med Sci. 2007;61(3):156-157
PubMed   |  Link to Article
Hampshire DJ, Roberts E, Crow Y,  et al.  Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36.  J Med Genet. 2001;38(10):680-682
PubMed   |  Link to Article
Bonifati V. Autosomal recessive parkinsonism.  Parkinsonism Relat Disord. 2012;18:(suppl 1)  S4-S6
PubMed   |  Link to Article
Schneider SA, Bhatia KP, Hardy J. Complicated recessive dystonia parkinsonism syndromes.  Mov Disord. 2009;24(4):490-499
PubMed   |  Link to Article
Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders.  Neurobiol Dis. 2012;46(1):1-18
PubMed   |  Link to Article
Di Fonzo A, Dekker MC, Montagna P,  et al.  FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome.  Neurology. 2009;72(3):240-245
PubMed   |  Link to Article
Zhao T, De Graaff E, Breedveld GJ,  et al.  Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15).  PLoS One. 2011;6(2):e16983
PubMed   |  Link to Article
Paisán-Ruiz C, Guevara R, Federoff M,  et al.  Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.  Mov Disord. 2010;25(12):1791-1800
PubMed   |  Link to Article
Luo LZ, Xu Q, Guo JF,  et al.  FBXO7 gene mutations may be rare in Chinese early-onset Parkinsonism patients.  Neurosci Lett. 2010;482(2):86-89
PubMed   |  Link to Article
Hsu JM, Lee YC, Yu CT, Huang CY. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region.  J Biol Chem. 2004;279(31):32592-32602
PubMed   |  Link to Article
Chang YF, Cheng CM, Chang LK, Jong YJ, Yuo CY. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination.  Biochem Biophys Res Commun. 2006;342(4):1022-1026
PubMed   |  Link to Article
Kirk R, Laman H, Knowles PP,  et al.  Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor.  J Biol Chem. 2008;283(32):22325-22335
PubMed   |  Link to Article
Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers?  Neurology. 2007;69(15):1542-1550
PubMed   |  Link to Article
Zaiss DM, Standera S, Kloetzel PM, Sijts AJ. PI31 is a modulator of proteasome formation and antigen processing.  Proc Natl Acad Sci U S A. 2002;99(22):14344-14349
PubMed   |  Link to Article
Laman H. Fbxo7 gets proactive with cyclin D/cdk6.  Cell Cycle. 2006;5(3):279-282
PubMed   |  Link to Article
Smith PD, O’Hare MJ, Park DS. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease.  Trends Mol Med. 2004;10(9):445-451
PubMed   |  Link to Article
Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.  Biochim Biophys Acta. 2009;1792(7):664-675
PubMed   |  Link to Article

Figures

Place holder to copy figure label and caption
Graphic Jump Location

Figure. Transcript 1 and isoform 1 of FBXO7. CDK indicates cyclin-dependent protein kinase 6 binding site; FP, FBXO7/PI31 domain; PRR, proline-rich region; and Ubl, ubiquitin-like domain.

Tables

Table Graphic Jump LocationTable 1. Genetic Loci and Genes Associated With Monogenic Forms of Parkinson Disease38
Table Graphic Jump LocationTable 2. Pathogenic Mutations in the FBXO7 Gene in Patients With Parkinsonian-Pyramidal Disease

References

Yang YX, Wood NW, Latchman DS. Molecular basis of Parkinson's disease.  Neuroreport. 2009;20(2):150-156
PubMed   |  Link to Article
Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease.  Ann Neurol. 2003;53:(suppl 3)  S16-S23, discussion S23-S25
PubMed   |  Link to Article
International Parkinson Disease Genomics Consortium. Nalls MA, Plagnol V, Hernandez DG,  et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.  Lancet. 2011;377(9766):641-649
PubMed   |  Link to Article
Simón-Sánchez J, Schulte C, Bras JM,  et al.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.  Nat Genet. 2009;41(12):1308-1312
PubMed   |  Link to Article
Vilariño-Güell C, Wider C, Ross OA,  et al.  VPS35 mutations in Parkinson disease.  Am J Hum Genet. 2011;89(1):162-167
PubMed   |  Link to Article
Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C,  et al.  Translation initiator EIF4G1 mutations in familial Parkinson disease.  Am J Hum Genet. 2011;89(3):398-406
PubMed   |  Link to Article
Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis.  Annu Rev Pathol. 2011;6:193-222
PubMed   |  Link to Article
Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease.  Annu Rev Genomics Hum Genet. 2011;12:301-325
PubMed   |  Link to Article
Jankovic J. Parkinson's disease: clinical features and diagnosis.  J Neurol Neurosurg Psychiatry. 2008;79(4):368-376
PubMed   |  Link to Article
Shojaee S, Sina F, Banihosseini SS,  et al.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays.  Am J Hum Genet. 2008;82(6):1375-1384
PubMed   |  Link to Article
Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C. cDNA cloning and expression analysis of new members of the mammalian F-box protein family.  Genomics. 2000;67(1):40-47
PubMed   |  Link to Article
Davison C. Pallido-pyramidal disease.  J Neuropathol Exp Neurol. 1954;13(1):50-59
PubMed   |  Link to Article
Kalita J, Misra UK, Das BK. Sporadic variety of pallido-pyramidal syndrome.  Neurol India. 2003;51(3):383-384
PubMed
Horowitz G, Greenberg J. Pallido-pyramidal syndrome treated with levodopa.  J Neurol Neurosurg Psychiatry. 1975;38(3):238-240
PubMed   |  Link to Article
Horstink MW, Dekker MC, Montagna P, Bonifati V, van De Warrenburg BP. Pallidopyramidal disease: a misnomer?  Mov Disord. 2010;25(9):1109-1115
PubMed   |  Link to Article
Panagariya A, Sharma B, Dev A. Pallido-pyramidal syndrome: a rare entity.  Indian J Med Sci. 2007;61(3):156-157
PubMed   |  Link to Article
Hampshire DJ, Roberts E, Crow Y,  et al.  Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36.  J Med Genet. 2001;38(10):680-682
PubMed   |  Link to Article
Bonifati V. Autosomal recessive parkinsonism.  Parkinsonism Relat Disord. 2012;18:(suppl 1)  S4-S6
PubMed   |  Link to Article
Schneider SA, Bhatia KP, Hardy J. Complicated recessive dystonia parkinsonism syndromes.  Mov Disord. 2009;24(4):490-499
PubMed   |  Link to Article
Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders.  Neurobiol Dis. 2012;46(1):1-18
PubMed   |  Link to Article
Di Fonzo A, Dekker MC, Montagna P,  et al.  FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome.  Neurology. 2009;72(3):240-245
PubMed   |  Link to Article
Zhao T, De Graaff E, Breedveld GJ,  et al.  Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15).  PLoS One. 2011;6(2):e16983
PubMed   |  Link to Article
Paisán-Ruiz C, Guevara R, Federoff M,  et al.  Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.  Mov Disord. 2010;25(12):1791-1800
PubMed   |  Link to Article
Luo LZ, Xu Q, Guo JF,  et al.  FBXO7 gene mutations may be rare in Chinese early-onset Parkinsonism patients.  Neurosci Lett. 2010;482(2):86-89
PubMed   |  Link to Article
Hsu JM, Lee YC, Yu CT, Huang CY. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region.  J Biol Chem. 2004;279(31):32592-32602
PubMed   |  Link to Article
Chang YF, Cheng CM, Chang LK, Jong YJ, Yuo CY. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination.  Biochem Biophys Res Commun. 2006;342(4):1022-1026
PubMed   |  Link to Article
Kirk R, Laman H, Knowles PP,  et al.  Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor.  J Biol Chem. 2008;283(32):22325-22335
PubMed   |  Link to Article
Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers?  Neurology. 2007;69(15):1542-1550
PubMed   |  Link to Article
Zaiss DM, Standera S, Kloetzel PM, Sijts AJ. PI31 is a modulator of proteasome formation and antigen processing.  Proc Natl Acad Sci U S A. 2002;99(22):14344-14349
PubMed   |  Link to Article
Laman H. Fbxo7 gets proactive with cyclin D/cdk6.  Cell Cycle. 2006;5(3):279-282
PubMed   |  Link to Article
Smith PD, O’Hare MJ, Park DS. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease.  Trends Mol Med. 2004;10(9):445-451
PubMed   |  Link to Article
Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.  Biochim Biophys Acta. 2009;1792(7):664-675
PubMed   |  Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 7

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles